Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorBağcı, Elife Zerrin
dc.contributor.authorSen, S. Murat
dc.contributor.authorÇamurdan, Mehmet C.
dc.date.accessioned2022-05-11T14:28:29Z
dc.date.available2022-05-11T14:28:29Z
dc.date.issued2013
dc.identifier.issn1387-1307
dc.identifier.issn1573-2614
dc.identifier.urihttps://doi.org/10.1007/s10877-013-9468-z
dc.identifier.urihttps://hdl.handle.net/20.500.11776/6843
dc.descriptionSCAI 10th International Conference on Complexity in Acute Illness (ICCAI) -- SEP, 2011 -- Bonn, GERMANYen_US
dc.description.abstractApoptosis is an important area of research because of its role in keeping a mature multicellular organism's number of cells constant, hence, ensuring that the organism does not have cell accumulation that may transform into cancer with additional hallmarks. Firstly, we have carried out sensitivity analysis on an existing mathematical mitochondria-dependent apoptosis model to find out which parameters have a role in causing monostable cell survival, which may, in turn, lead to malfunction in apoptosis. We have then generated three base parameter sets that represent healthy cells. These parameter sets were built by changing the sensitive parameters while preserving the bistability. For each base set, we varied the proapoptotic and antiapoptotic production rates, to yield new sets for the cells that have malfunctioning apoptosis. In a hypothetical cell model, we simulated caspase-3 activation by numerically integrating the governing ordinary differential equations of a mitochondria-dependent apoptosis model. These simulations were carried out for four potential treatments, namely: (1) proteasome inhibitor treatment, (2) Bcl-2 inhibitor treatment, (3) IAP inhibitor treatment, (4) Bid-like synthetic peptides treatment. The results suggest that the proteasome inhibitor treatment is the most effective treatment, though it may have severe side effects. For this treatment, the amount of proteasome inhibitor needed for caspase-3 activation may be different for hypothetical cells with a different pro- or anti-apoptotic protein defect. It is also found that caspase-3 can be activated by Bcl-2 inhibitor treatment only in those hypothetical malfunctioning cells with Bax deficiency but not in others. These results are in line with the view that molecular heterogeneity in individuals may be an important factor in determining the individuals' positive or negative responses to treatments.en_US
dc.description.sponsorshipSoc Complex Acute Illness (SCAI)en_US
dc.language.isoengen_US
dc.publisherSpringer Heidelbergen_US
dc.identifier.doi10.1007/s10877-013-9468-z
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSimulations of apoptosis malfunctionen_US
dc.subjectVariability in individualsen_US
dc.subjectTreatments of malfunction in apoptosisen_US
dc.subjectCaspase Activationen_US
dc.subjectPathwayen_US
dc.subjectCanceren_US
dc.subjectMitochondrialen_US
dc.subjectBistabilityen_US
dc.subjectMechanismsen_US
dc.subjectSimulationen_US
dc.subjectResistanceen_US
dc.subjectDynamicsen_US
dc.subjectSurvivalen_US
dc.titleAnalysis of a mathematical model of apoptosis: individual differences and malfunction in programmed cell deathen_US
dc.typeproceedingPaperen_US
dc.relation.ispartofJournal of Clinical Monitoring and Computingen_US
dc.departmentFakülteler, Fen Edebiyat Fakültesi, Biyoloji Bölümüen_US
dc.authorid0000-0001-5920-0400
dc.identifier.volume27en_US
dc.identifier.issue4en_US
dc.identifier.startpage465en_US
dc.identifier.endpage479en_US
dc.institutionauthorBağcı, Elife Zerrin
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.authorscopusid8754351000
dc.authorscopusid54279389500
dc.authorscopusid6604017391
dc.authorwosidBağcı, Elife Zerrin/A-9660-2016
dc.identifier.wosWOS:000321261400012en_US
dc.identifier.scopus2-s2.0-84879552009en_US
dc.identifier.pmid23604638en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster